Abstracts tagged "autoantibodies"

Abstract Number: 638 • 2014 ACR/ARHP Annual Meeting
Commensal Microbiota Influence Systemic Autoimmune Responses
Jens Van Praet¹, Erin Donovan², Michael Drennan¹, Fons Van de Loo³, Sylvie Rabot⁴, Jeroen Raes⁵, Tom Van De Wiele⁶, Carl Ware⁷ and Dirk Elewaut⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²department of Rheumatology, Ghent University Hospital, ghent, Belgium, ³Rheumatology, Raboud University Medical Center, Utrecht, Netherlands, ⁴AgroParisTech, Micalis,, Jouy-en-Josas, France, ⁵Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium, ⁶Laboratory of Microbial Ecology and Technology, Ghent University Hospital, Ghent, Belgium, ⁷Infectious and Inflammatory Disease Center,, Sanford-Burnham Medical Research Institute, La Jolla, CA, ⁸Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose Antinuclear antibodies are a hallmark feature of generalized autoimmune diseases, including systemic lupus erythematosus and systemic sclerosis. However, the processes underlying the loss of…
Abstract Number: 2530 • 2014 ACR/ARHP Annual Meeting
PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors
Karl Skriner¹, Jörg Hollidt², Gerd Burmester³ and Zoltan Konthur⁴, ¹Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Drug Response DX GmbH, Hennigsdorf, Germany
Background/Purpose One third of rheumatoid arthritis patients treated with biologicals targeting TNFα are therapy non-responders. We have earlier investigated the difference in seroreactivity of patients…
Abstract Number: 1272 • 2014 ACR/ARHP Annual Meeting
Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis
Puja Srivastava, Ramnath Misra, Able Lawrence, Amita Aggarwal and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose Recently, idiopathic inflammatory myositis (IIM) has been categorised into distinct subsets based on myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA). However, there is…
Abstract Number: 442 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels
Gregory J. Challener¹, Jonathan D. Jones², B. JoNell Hamilton¹, Gilles Boire³, Artur José de Brum-Fernandes⁴, Pierre Cossette⁵, Patrick Liang³, Ariel Masetto⁶, Nathalie Carrier⁷, Henri A. Ménard⁸ and William F.C. Rigby⁹, ¹Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ²Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Médecine, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, Research Institute of the McGill University Health Center, Montreal, QC, Canada, ⁹Rheumatology; Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH
Background/Purpose: Recent studies indicate that the breach of immune tolerance that occurs in rheumatoid arthritis (RA) extends beyond the citrullination of arginines (as recognized by…
Abstract Number: 2457 • 2014 ACR/ARHP Annual Meeting
Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Hiroshi Furukawa¹, Shomi Oka¹, Kota Shimada², Akiko Komiya¹, Naoshi Fukui¹, Naoyuki Tsuchiya³ and Shigeto Tohma¹, ¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ³Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD) that influences the prognosis of the disease.…
Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 455 • 2014 ACR/ARHP Annual Meeting
Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis
Antonio Gonzalez¹, Ariana Montes¹, Eva Perez-Pampin¹, Maria Dolores Boveda² and Juan J. Gomez-Reino^1,3, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Laboratorio Metabolopatias, Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose Antibodies against carbamylated proteins (CarP) are a new type of autoantibodies specific of patients with rheumatoid arthritis (RA) relative to healthy controls, but their…
Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Marije K Verheul², Anne Barton^3,4, Tarnya Marshall⁵, Bo Fu⁶, René E.M. Toes⁷, Deborah PM Symmons^1,4, Leendert A. Trouw⁷ and Suzanne MM Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁶Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia. However, little is known about their association with disease…
Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Yuji Hosono¹, Ran Nakashima², Yoshitaka Imura³, Naoichiro Yukawa², Hajime Yoshifuji², Takaki Nojima⁴, Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…
Abstract Number: 454 • 2014 ACR/ARHP Annual Meeting
The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis
Jing Shi, H.W. van Steenbergen, J. a. B. van Nies, E.W.Nivine Levarht, Annette H. M. van der Helm- van Mil, Tom W. J. Huizinga, René E.M. Toes and Leendert A. Trouw, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid arthritis (RA) and arthralgia patients [1;2] and occur in subsets of the anti-CCP2 positive and…
Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting
Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…
Abstract Number: 1257 • 2014 ACR/ARHP Annual Meeting
A New Multianalyte Assay for Detection of Dermatomyositis-Specific Autoantibodies Undetectable By Commercially Available Immunoassays
Masataka Kuwana¹, Yuka Okazaki² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The disease expression of dermatomyositis (DM) is highly variable among patients, ranging form those with severe muscle weakness in the absence of internal organ…
Abstract Number: 387 • 2014 ACR/ARHP Annual Meeting
Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Caroline Grönwall¹, Lelise Getu², Jeffrey D. Greenberg³, Robert M. Clancy⁴ and Gregg J. Silverman¹, ¹Medicine, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Monitoring disease activity in patients with autoimmune rheumatic disease is an essential part of clinical care. Highly reactive malondialdehyde (MDA) arise from reactive oxygen…
Abstract Number: 2016 • 2014 ACR/ARHP Annual Meeting
Occupation and Risk of Developing Rheumatoid Arthritis
Anna Ilar¹, Pernilla Wiebert¹, Lars Klareskog², Lars Alfredsson¹ and Camilla Bengtsson¹, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose The role of environmental factors in the etiology of rheumatoid arthritis (RA) is still fairly unknown. Finding occupations associated with the risk of disease…
Abstract Number: 1255 • 2014 ACR/ARHP Annual Meeting
Pathogenic Role of Tyrosyl–Transfer RNA Synthetase in Anti-Synthetase Syndrome
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Manabu Kawamoto¹, Ken Iwaki², Miki Miyanokoshi², Keisuke Wakasugi², Koji Tahara³, Kaori Ito³, Hiroaki Hattori³, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan, ³Advanced Medical Technology and Development, BML, Saitama, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose : Autoantibodies directed against the aminoacyl transfer RNA (tRNA) synthetases are associated with myositis, arthritis, Raynaud’s phenomenon, mechanic’s hands, fever, and interstitial lung disease,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].